HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. ®

First Page		Document Content
Date: 2012-08-15 16:02:36 Gilead Sciences Carbamates Non-nucleoside reverse transcriptase inhibitors Integrase inhibitors Raltegravir Tenofovir Efavirenz Darunavir Antiretroviral drug Chemistry Organic chemistry Organofluorides		HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. ® Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 687,07 KB Share Document on Facebook

	January 22, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Gilead Sciences, Galapagos Close $2 Billion Deal for AntiInfla DocID: 1rBxh - View Document
	Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No DocID: 1rqYi - View Document
	March 4, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. Sponsored By: DocID: 1rdax - View Document
	Microsoft Word - GILEAD BRIEFING DocID: 1r2Vm - View Document
	Patient Name:________________________________________ Date of Birth:__________________ Truvada® for Pre-Exposure Prophylaxis (PrEP) Medication Assistance Program Page 1 of 4 DocID: 1qMRc - View Document